Company profile BLPH
After 39 days of this quarter the interest is at 38.0. Based on that we can calculate that during remaining 52 days it will total up to 89.0. Bellerophon Therapeutics expected interest is significantly higher compared to previous quarter (+122.5%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 15 | 80 433.3% QoQ | 107 33.8% QoQ | 94 -12.1% QoQ |
| 2020 | 281 1773.3% YoY 198.9% QoQ | 211 163.8% YoY -24.9% QoQ | 66 -38.3% YoY -68.7% QoQ | 11 -88.3% YoY -83.3% QoQ |
| 2021 | 65 -76.9% YoY 490.9% QoQ | 66 -68.7% YoY 1.5% QoQ | 48 -27.3% YoY -27.3% QoQ | 111 909.1% YoY 131.2% QoQ |
| 2022 | 53 -18.5% YoY -52.3% QoQ | 83 25.8% YoY 56.6% QoQ | 119 147.9% YoY 43.4% QoQ | 61 -45.0% YoY -48.7% QoQ |
| 2023 | 102 92.5% YoY 67.2% QoQ | 55 -33.7% YoY -46.1% QoQ | 79 -33.6% YoY 43.6% QoQ | 40 -34.4% YoY -49.4% QoQ |
| 2024 | 38 -62.7% YoY -5.0% QoQ | - | - | - |
The average 5 years interest of Bellerophon Therapeutics was 6.84 per week. The last year interest of Bellerophon Therapeutics compared to the last 5 years has changed by -21.49%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -10.8%.
There is not enough data for Bellerophon Therapeutics INOpulse to provide analysis
There is not enough data for Bellerophon Therapeutics INOpulse to provide correlation calculation
There is not enough data for Bellerophon Therapeutics INOpulse to provide analysis
There is not enough data for INOpulse clinical trials to provide analysis
There is not enough data for INOpulse clinical trials to provide correlation calculation
There is not enough data for INOpulse clinical trials to provide analysis
After 92 days of this quarter the interest is at 613.0. Based on that we can calculate that during remaining 0 days it will total up to 613.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 557 |
| 2019 | 697 25.1% QoQ | 652 -6.5% QoQ | 697 6.9% QoQ | 553 -0.7% YoY -20.7% QoQ |
| 2020 | 644 -7.6% YoY 16.5% QoQ | 399 -38.8% YoY -38.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2022 | 356 inf% YoY inf% QoQ | 620 inf% YoY 74.2% QoQ | 719 inf% YoY 16.0% QoQ | 575 inf% YoY -20.0% QoQ |
| 2023 | 692 94.4% YoY 20.3% QoQ | 732 18.1% YoY 5.8% QoQ | 613 -14.7% YoY -16.3% QoQ | 108 -81.2% YoY -82.4% QoQ |
The average 5 years interest of Pulmonary hypertension treatment was 33.13 per week. The last year interest of Pulmonary hypertension treatment compared to the last 5 years has changed by 53.0%. The interest for Pulmonary hypertension treatment is trending. The last year interest is comparable to 5 years ago. It has changed only by -2.48%.
After 39 days of this quarter the interest is at 227.0. Based on that we can calculate that during remaining 52 days it will total up to 530.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 303 | 585 93.1% QoQ | 618 5.6% QoQ | 567 -8.3% QoQ |
| 2020 | 664 119.1% YoY 17.1% QoQ | 459 -21.5% YoY -30.9% QoQ | 532 -13.9% YoY 15.9% QoQ | 459 -19.0% YoY -13.7% QoQ |
| 2021 | 491 -26.1% YoY 7.0% QoQ | 470 2.4% YoY -4.3% QoQ | 477 -10.3% YoY 1.5% QoQ | 498 8.5% YoY 4.4% QoQ |
| 2022 | 570 16.1% YoY 14.5% QoQ | 477 1.5% YoY -16.3% QoQ | 597 25.2% YoY 25.2% QoQ | 570 14.5% YoY -4.5% QoQ |
| 2023 | 571 0.2% YoY 0.2% QoQ | 626 31.2% YoY 9.6% QoQ | 575 -3.7% YoY -8.1% QoQ | 592 3.9% YoY 3.0% QoQ |
| 2024 | 227 -60.2% YoY -61.7% QoQ | - | - | - |
The average 5 years interest of Pulmonary hypertension causes was 41.87 per week. The last year interest of Pulmonary hypertension causes compared to the last 5 years has changed by 7.93%. The interest for Pulmonary hypertension causes is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 0.65%.
After 39 days of this quarter the interest is at 92.0. Based on that we can calculate that during remaining 52 days it will total up to 215.0. Cardiopulmonary diseases expected interest is significantly higher compared to previous quarter (+95.5%) and same quarter last year (+76.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 71 | 0 -100.0% QoQ | 50 inf% QoQ | 0 -100.0% QoQ |
| 2020 | 141 98.6% YoY inf% QoQ | 127 inf% YoY -9.9% QoQ | 80 60.0% YoY -37.0% QoQ | 28 inf% YoY -65.0% QoQ |
| 2021 | 126 -10.6% YoY 350.0% QoQ | 78 -38.6% YoY -38.1% QoQ | 227 183.8% YoY 191.0% QoQ | 119 325.0% YoY -47.6% QoQ |
| 2022 | 114 -9.5% YoY -4.2% QoQ | 16 -79.5% YoY -86.0% QoQ | 111 -51.1% YoY 593.8% QoQ | 56 -52.9% YoY -49.5% QoQ |
| 2023 | 122 7.0% YoY 117.9% QoQ | 149 831.2% YoY 22.1% QoQ | 87 -21.6% YoY -41.6% QoQ | 110 96.4% YoY 26.4% QoQ |
| 2024 | 92 -24.6% YoY -16.4% QoQ | - | - | - |
The average 5 years interest of Cardiopulmonary diseases was 7.3 per week. The last year interest of Cardiopulmonary diseases compared to the last 5 years has changed by 47.53%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 259.0%.
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. Bellerophon Therapeutics stock expected interest is significantly higher compared to previous quarter (+1692.3%) and same quarter last year (+1270.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 20 | 47 135.0% QoQ | 36 -23.4% QoQ | 111 208.3% QoQ |
| 2020 | 114 470.0% YoY 2.7% QoQ | 62 31.9% YoY -45.6% QoQ | 108 200.0% YoY 74.2% QoQ | 28 -74.8% YoY -74.1% QoQ |
| 2021 | 117 2.6% YoY 317.9% QoQ | 71 14.5% YoY -39.3% QoQ | 117 8.3% YoY 64.8% QoQ | 46 64.3% YoY -60.7% QoQ |
| 2022 | 56 -52.1% YoY 21.7% QoQ | 29 -59.2% YoY -48.2% QoQ | 40 -65.8% YoY 37.9% QoQ | 82 78.3% YoY 105.0% QoQ |
| 2023 | 17 -69.6% YoY -79.3% QoQ | 25 -13.8% YoY 47.1% QoQ | 42 5.0% YoY 68.0% QoQ | 13 -84.1% YoY -69.0% QoQ |
| 2024 | 100 488.2% YoY 669.2% QoQ | - | - | - |
The average 5 years interest of Bellerophon Therapeutics stock was 4.91 per week. The last year interest of Bellerophon Therapeutics stock compared to the last 5 years has changed by -29.53%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -21.0%.
After 39 days of this quarter the interest is at 67.0. Based on that we can calculate that during remaining 52 days it will total up to 156.0. Bellerophon Therapeutics news expected interest is significantly higher compared to previous quarter (+62.5%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 245 inf% QoQ | 322 31.4% QoQ | 321 -0.3% QoQ |
| 2020 | 90 inf% YoY -72.0% QoQ | 41 -83.3% YoY -54.4% QoQ | 227 -29.5% YoY 453.7% QoQ | 135 -57.9% YoY -40.5% QoQ |
| 2021 | 35 -61.1% YoY -74.1% QoQ | 37 -9.8% YoY 5.7% QoQ | 131 -42.3% YoY 254.1% QoQ | 58 -57.0% YoY -55.7% QoQ |
| 2022 | 264 654.3% YoY 355.2% QoQ | 180 386.5% YoY -31.8% QoQ | 125 -4.6% YoY -30.6% QoQ | 281 384.5% YoY 124.8% QoQ |
| 2023 | 136 -48.5% YoY -51.6% QoQ | 0 -100.0% YoY -100.0% QoQ | 191 52.8% YoY inf% QoQ | 96 -65.8% YoY -49.7% QoQ |
| 2024 | 67 -50.7% YoY -30.2% QoQ | - | - | - |
The average 5 years interest of Bellerophon Therapeutics news was 11.43 per week. The last year interest of Bellerophon Therapeutics news compared to the last 5 years has changed by -33.51%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -55.5%.
There is not enough data for Bellerophon Therapeutics reviews to provide analysis
There is not enough data for Bellerophon Therapeutics reviews to provide correlation calculation
There is not enough data for Bellerophon Therapeutics reviews to provide analysis
There is not enough data for Bellerophon Therapeutics contact to provide analysis
There is not enough data for Bellerophon Therapeutics contact to provide correlation calculation
There is not enough data for Bellerophon Therapeutics contact to provide analysis